Featured Research

from universities, journals, and other organizations

Lung Cancer Oncogene Holds Key To Turning Off Cancer Stem Cells

Date:
September 10, 2009
Source:
Mayo Clinic
Summary:
Scientists have found that the lung cancer oncogene PKCiota is necessary for the proliferation of lung cancer stem cells. These stem cells are rare and powerful master cells that manufacture the other cells that make up lung tumors and are resistant to chemotherapy treatment.

Scientists at the Mayo Clinic campus in Florida have found that the lung cancer oncogene PKCiota is necessary for the proliferation of lung cancer stem cells. These stem cells are rare and powerful master cells that manufacture the other cells that make up lung tumors and are resistant to chemotherapy treatment.

Their study, published in the Oct. 1 issue of Cancer Research, also shows that an agent, aurothiomalate, being tested at Mayo Clinic in a phase I clinical trial substantially inhibits growth of these cancer stem cells.

"Our data indicate that PKCiota is required for the earliest steps in the development of lung cancer, which is the expansion of tumor-initiating cells or cancer stem cells," says the study's senior author, Alan Fields, Ph.D., professor of pharmacology in the College of Medicine, Mayo Clinic, and chair of the Department of Cancer Biology at Mayo Clinic's campus in Florida.

"Lung cancer stem cells appear to be the major drivers in many common lung cancers, and in order for a therapeutic treatment to be effective, it has to disrupt these cancer stem cells," he says. "We show that aurothiomalate, the agent now being tested in lung cancer patients, can, in fact, target these cells."

Aurothiomalate was once used to treat rheumatoid arthritis, but the Mayo Clinic researchers discovered by screening thousands of Food and Drug Administration-approved drugs that it also can target PKCiota. The agent is being tested in patients at Mayo Clinic's sites in Minnesota and Arizona and, based on this phase I trial, a phase II human clinical trial is planned to combine aurothiomalate with agents targeted at other molecules involved in cancer growth.

Dr. Fields and his colleagues were the first to discover that PKCiota is a human oncogene — an abnormal gene that cancer cells use to grow and/or survive. They found that PKCiota is genetically altered and over-expressed in a majority of lung cancers and that over-expression of the PKCiota gene in tumors predicts poor patient survival.

"We had previously shown that PKCiota is required to maintain tumor growth, but what this study sought to determine is whether PKCiota is involved in the initial steps of lung cancer development," Dr. Fields says.

Cancer stem cells are thought to hold the key not only to how lung tumors initially arise but also to how they are maintained and become resistant to treatment. Cancer stem cells are self-renewing and can also give rise to the cells that make up most of a tumor. In mice, an oncogene known as Kras is thought to transform normal lung stem cells into cancer stem cells, thereby initiating lung cancer, according to Dr. Fields. In the present study, the Mayo researchers established a strain of mice in which Kras can be activated at the same time that the PKCiota gene is inactivated. They found that when the PKCiota gene is inactivated, Kras was unable to cause errant growth and expansion of lung stem cells in mice, the process that initiates tumor formation.

"What this told us is that Kras requires PKCiota to transform the lung stem cells and make them proliferate," Dr. Fields says. "In other words, PKCiota is downstream from Kras, and is necessary for Kras to initiate lung tumor formation."

Because Dr. Fields and his colleagues had discovered that aurothiomalate disables PKCiota, they tested whether this agent is effective against lung cancer that develops due to Kras mutation. "The drug showed potent inhibitory effects on the Kras-dependent proliferation of lung cancer stem cells both in cell culture and in animals," Dr. Fields says.

"That further suggests that a drug like aurothiomalate could have an effect on tumors that are dependent on either Kras or PKCiota for growth and survival, and that is potentially a lot of cancers," he says. "Aurothiomalate appears to be one of the few drugs available that can effectively target these critical cancer stem cells. In the clinic, however, it is likely that aurothiomalate will be most effective when combined with other agents designed to target other tumor survival pathways."

The study was funded by grants from the National Cancer Institute, the V-Foundation and the American Lung Association/LUNGevity. Other Mayo Clinic researchers who participated in the study were Roderick Regala, Ph.D., Rebecca Davis, Ph.D., Alyssa Kunz, and Andras Khoor, M.D. Also collaborating on the study was Michael Leitges, Ph.D., of the University of Oslo.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Lung Cancer Oncogene Holds Key To Turning Off Cancer Stem Cells." ScienceDaily. ScienceDaily, 10 September 2009. <www.sciencedaily.com/releases/2009/09/090908132233.htm>.
Mayo Clinic. (2009, September 10). Lung Cancer Oncogene Holds Key To Turning Off Cancer Stem Cells. ScienceDaily. Retrieved August 2, 2014 from www.sciencedaily.com/releases/2009/09/090908132233.htm
Mayo Clinic. "Lung Cancer Oncogene Holds Key To Turning Off Cancer Stem Cells." ScienceDaily. www.sciencedaily.com/releases/2009/09/090908132233.htm (accessed August 2, 2014).

Share This




More Health & Medicine News

Saturday, August 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Quintuplets Head Home

Texas Quintuplets Head Home

Reuters - US Online Video (Aug. 1, 2014) After four months in the hospital, the first quintuplets to be born at Baylor University Medical Center head home. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Patient Coming to U.S. for Treatment

Ebola Patient Coming to U.S. for Treatment

Reuters - US Online Video (Aug. 1, 2014) A U.S. aid worker infected with Ebola while working in West Africa will be treated in a high security ward at Emory University in Atlanta. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins